Brachytherapy

Global Nuclear Medicine Market Size, Share & Trends Analysis Report 2022: A $24.4 Billion Market by 2030 - Impending Approval of Multiple Radiopharmaceutical Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy), by Application, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy), by Application, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market.
  • For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer.
  • Increasing adoption of nuclear medicine products in diagnosis and the approval of new generators to help increase the supply of radionuclides is expected to drive growth.

Brainlab Announces the Majority Acquisition of medPhoton

Retrieved on: 
Thursday, May 12, 2022

Brainlab , a digital medical technology company, announced today the majority acquisition of medPhoton GmbH , a Salzburg, Austria-based company, that develops and manufactures robotic imaging solutions for image guided radiation therapy and surgery.

Key Points: 
  • Brainlab , a digital medical technology company, announced today the majority acquisition of medPhoton GmbH , a Salzburg, Austria-based company, that develops and manufactures robotic imaging solutions for image guided radiation therapy and surgery.
  • Over the last years, medPhoton has maintained a close partnership with Brainlab in the field of intraoperative imaging.
  • Brainlab strategically invested in medPhoton, co-funded the development of Loop-X and became the exclusive distributor of the mobile imaging robot in the field of surgery.
  • View the full release here: https://www.businesswire.com/news/home/20220512005766/en/
    "Through the completion of this majority acquisition, we want to build on the previous success of Loop-X and decisively shape the future of intraoperative imaging," said Stefan Vilsmeier, President and CEO of Brainlab.

Vivos Inc. Provides Intellectual Property Protection Update

Retrieved on: 
Thursday, May 12, 2022

Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts.

Key Points: 
  • Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts.
  • This year we also filed a provisional patent number 63-299,930 giving us broader protection on recent and projected developments on both our hydrogel and our particle components.
  • This week we filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet) and in humans (RadioGel).

Isoray Announces Record Third Quarter Fiscal 2022 Financial Results

Retrieved on: 
Tuesday, May 10, 2022

RICHLAND, Wash., May 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced its financial results for the third quarter of fiscal 2022 ended March 31, 2022.

Key Points: 
  • RICHLAND, Wash., May 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced its financial results for the third quarter of fiscal 2022 ended March 31, 2022.
  • Revenue for the third quarter of fiscal 2022 grew 12% to $2.91 million versus $2.60 million in the prior year comparable period.
  • Prostate brachytherapy represented 75% of total revenue for the third quarter of fiscal 2022 compared to 78% in the prior year comparable period.
  • Third quarter gross profit increased 5.8% to $1.44 million versus $1.36 million in the third quarter of fiscal 2021.

Varian Highlights Comprehensive Cancer Care Portfolio at ESTRO 2022

Retrieved on: 
Thursday, May 5, 2022

PALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, will be showcasing its comprehensive cancer care portfolio at the 2022 annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), starting tomorrow in Copenhagen, Denmark. The combined company's exhibit will highlight technologies that span the entire cancer care continuum, from screening and prevention, through diagnosis, therapy, and survivorship. In addition to driving speed and precision, these solutions seek to streamline workflows and empower cancer care teams to improve their clinical and operational performance and meet unique and evolving patient needs.

Key Points: 
  • Showcases Innovative Technologies and Services to Drive Personalization, Precision, and Connectivity Along the Radiotherapy Treatment Pathway
    PALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, will be showcasing its comprehensive cancer care portfolio at the 2022 annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), starting tomorrow in Copenhagen, Denmark.
  • The combined company's exhibit will highlight technologies that span the entire cancer care continuum, from screening and prevention, through diagnosis, therapy, and survivorship.
  • Additional innovative solutions from Varian and Siemens Healthineers that will be showcased at ESTRO, include:
    ARIA oncology information system, which has been reimagined as a comprehensive cancer care management tool.
  • We are working to harness advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care.

Varian Highlights Comprehensive Cancer Care Portfolio at ESTRO 2022

Retrieved on: 
Thursday, May 5, 2022

PALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, will be showcasing its comprehensive cancer care portfolio at the 2022 annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), starting tomorrow in Copenhagen, Denmark. The combined company's exhibit will highlight technologies that span the entire cancer care continuum, from screening and prevention, through diagnosis, therapy, and survivorship. In addition to driving speed and precision, these solutions seek to streamline workflows and empower cancer care teams to improve their clinical and operational performance and meet unique and evolving patient needs.

Key Points: 
  • Showcases Innovative Technologies and Services to Drive Personalization, Precision, and Connectivity Along the Radiotherapy Treatment Pathway
    PALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, will be showcasing its comprehensive cancer care portfolio at the 2022 annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), starting tomorrow in Copenhagen, Denmark.
  • The combined company's exhibit will highlight technologies that span the entire cancer care continuum, from screening and prevention, through diagnosis, therapy, and survivorship.
  • Additional innovative solutions from Varian and Siemens Healthineers that will be showcased at ESTRO, include:
    ARIA oncology information system, which has been reimagined as a comprehensive cancer care management tool.
  • We are working to harness advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care.

Latest innovations from RayStation, RayIntelligence and RayCare to be presented at ESTRO 2022

Retrieved on: 
Thursday, May 5, 2022

STOCKHOLM, May 5, 2022 /PRNewswire/ --RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ESTRO 2022, to be held in Copenhagen, May 6-10.

Key Points: 
  • STOCKHOLM, May 5, 2022 /PRNewswire/ --RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ESTRO 2022, to be held in Copenhagen, May 6-10.
  • Attendees will be able to book demonstrations of RayStation* treatment planning system, the cloud-based oncology analytics system RayIntelligence and RayCare* oncology information system during the congress.
  • New deep learning planning models have been released and deep learning segmentation is now included for free for all RayStation customers.
  • The RayCare* oncology information system (OIS) is designed to support the many complex logistical challenges faced by today's oncology clinics.

Vivos Inc Implements Multiple Patient IsoPet® Therapy Day

Retrieved on: 
Thursday, April 21, 2022

The Isopet treatments went smoothly from our single production run delivered via overnight delivery directly to the clinic.

Key Points: 
  • The Isopet treatments went smoothly from our single production run delivered via overnight delivery directly to the clinic.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet) and in humans (RadioGel).
  • Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.
  • Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet to University animal hospitals and private veterinary clinics.

Merit Medical Receives FDA Clearance for SCOUT Bx™ Delivery System

Retrieved on: 
Monday, April 11, 2022

SOUTH JORDAN, Utah, April 11, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, has received FDA clearance for the SCOUT Bx Delivery System, the first wire-free breast localization solution that can be deployed at the time of stereotactic or MRI-guided biopsy.

Key Points: 
  • SOUTH JORDAN, Utah, April 11, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, has received FDA clearance for the SCOUT Bx Delivery System, the first wire-free breast localization solution that can be deployed at the time of stereotactic or MRI-guided biopsy.
  • SCOUT Bx is compatible with the most commonly used stereotactic and MRI guided breast biopsy devices on the market, allowing the patient to avoid an additional procedure.
  • The SCOUT Bx system is designed to allow clinicians to offer this streamlined pathway to a broader group of patients.
  • The SCOUT Bx system is the newest addition to the Merit Oncology Breast and Soft Tissue Localization portfolio.

The Worldwide Brachytherapy Treatment Planning Systems Industry is Expected to Reach $1.5 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 28, 2022

Some of the most commonly diagnosed cancer cases are breast cancer, prostate cancer, lung cancer, and colorectal cancer.

Key Points: 
  • Some of the most commonly diagnosed cancer cases are breast cancer, prostate cancer, lung cancer, and colorectal cancer.
  • The dramatically rising prevalence of cancer is boosting the demand for innovative cancer care therapies with precise and accurate outcomes.
  • The oncology care industry is witnessing a surge in innovations and investments by key participants developing novel technologies, which are anticipated to significantly transform the cancer care treatment regime.
  • Along with the growing prevalence of cancer, the rising number of radiotherapy centers with technologies for better brachytherapy treatment planning is boosting the market growth.